Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Bull Cancer ; 105(2): 162-170, 2018 Feb.
Article in French | MEDLINE | ID: mdl-29066086

ABSTRACT

Patients with chronic hepatitis B infection are at risk of viral reactivation when treated by immuno- or chemotherapy, with potentially serious or even fatal consequences. This article proposes an overview on screening strategies and antiviral treatment recommendations for oncology patients. We have learned in hematology that reactivations are commun with rituximab and prophylactic treatment is recommanded for any patient who has been in contact with the virus. The risk appears to be lower with cytotoxics but has been far less studied. The recommandations are not formally consensual and upcoming studies will help to establish clearer practice guidelines.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis B virus/drug effects , Hepatitis B, Chronic/diagnosis , Hepatitis B, Chronic/drug therapy , Neoplasms/drug therapy , Rituximab/therapeutic use , Virus Activation , Allografts , Anthracyclines/adverse effects , Anthracyclines/therapeutic use , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Antiviral Agents/adverse effects , Hematopoietic Stem Cell Transplantation , Hepatitis B Antigens/blood , Hepatitis B virus/immunology , Hepatitis B virus/physiology , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/virology , Humans , Rituximab/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...